J&J, Bayer Fail to Win U.S. Backing for Expanded XareltoAnna Edney
Johnson & Johnson and Bayer AG failed to win approval to expand use of their blood thinner Xarelto to prevent heart attacks and strokes in patients with serious chest pain or history of cardiac illness.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.